Health  Vol.9 No.7 , July 2017
What Is the Personal Experience of IBD Patients about Their Anti-TNF-Alpha Therapy?
AIM: To evaluate and compare the patients opinion on the two types of anti- TNF-α therapies in a Hungarian cohort of IBD patients. METHODS: This was a prospective, multicentre, questionnaire-based observational study carried out in three Hungarian tertiary centres. From April to September 2014, an anonymous questionnaire was distributed to patients diagnosed with ulcerative colitis (UC) or Crohn’s disease (CD), who have received infliximab (IFX) and/or adalimumab (ADA). The survey focused on the preferences of the two anti-TNF-α therapies on the basis of the efficacy, the administration routes and the side effects. RESULTS: 292 IBD patients, 216 CD, 75 UC and 1 indeterminate colitis patient completed the questionnaire. The mean duration of biological therapy was 1.7 (1 - 7) years. IFX treated patients noticed improvement of symptoms at 4 - 5 weeks while ADA treated patients noticed at 5 - 6 weeks. There was no difference between the patients’ satisfaction regarding the types of anti-TNF-α therapy if they received both. However, subcutaneous administration was preferred by ADA-treated patients previously receiving IFX (p = 0.007) compared to intravenous route and they did not intend to change the mode of therapy (p = 0.040). 90% of the patients, receiving only IFX or ADA were satisfied with their present therapy. The majority of patients (186/292, 63.7%) would not switch therapy. 63 of 291, 22% of the patients reported to have some concern with biological therapy—the majority (32/63, 50.8%) due to fear from side effects. CONCLUSION: Generally, patients preferred and would not change the present anti-TNF-α therapy, however, subcutaneous administration was preferred among those patients who had have experience with both.
Cite this paper: Milassin, Á. , Rutka, M. , Csontos, Á. , Miheller, P. , Palatka, K. , Szűcs, M. , Szepes, Z. , Bálint, A. , Bor, R. , Fábián, A. , Farkas, K. , Nagy, F. and Molnár, T. (2017) What Is the Personal Experience of IBD Patients about Their Anti-TNF-Alpha Therapy?. Health, 9, 1007-1018. doi: 10.4236/health.2017.97073.

[1]   Ananthakrishnan, A.N. (2013) Environmental Risk Factors for Inflammatory Bowel Disease. Journal of Gastroenterology and Hepatology, 9, 367-374.

[2]   Xavier, R.J. and Podolsky, D.K. (2007) Unravelling the Pathogenesis of Inflammatory Bowel Disease. Nature, 448, 427-434.

[3]   Rutgeerts, P., Feagan, B.G., Lichtenstein, G.R., et al. (2004) Comparison of Scheduled and Episodic Treatment Strategies of Infliximab in Crohn’s Disease. Gastroenterology, 126, 402-413.

[4]   Schnitzler, F., Fidder, H., Ferrante, M., et al. (2009) Mucosal Healing Predicts Long- Term Outcome of Maintenance Therapy with Infliximab in Crohn’s Disease. Inflammatory Bowel Diseases, 15, 1295-1301.

[5]   Allen, P.B., Lindsay, H. and Tham, T.C. (2010) How Do Patients with Inflammatory Bowel Disease Want Their Biological Therapy Administered? BMC Gastroenterology, 10, 1.

[6]   Vavricka, S.R., Bentele, N., Scharl, M., et al. (2012) Systematic Assessment of Factors Influencing Preferences of Crohn’s Disease Patients in Selecting an Anti-Tu- mor Necrosis Factor Agent (CHOOSE TNF TRIAL). Inflammatory Bowel Diseases, 18, 1523-1530.

[7]   Satsangi, J., Silverberg, M.S., Vermeire, S., et al. (2006) The Montreal Classification of Inflammatory Bowel Disease: Controversies, Consensus, and Implications. Gut, 55, 749-753.

[8]   Chilton, F. and Collett, R.A. (2008) Treatment Choices, Preferences and Decision- Making by Patients with Rheumatoid Arthritis. Musculoskeletal Care, 6, 1-14.

[9]   William, E.L. and Edward, C.J. (2006) Patient Preferences in Choosing Anti-TNF Therapies-R1. Rheumatology (Oxford), 45, 1575-1576.

[10]   Jackson, C.A., Clatworthy, J., Robinson, A., et al. (2010) Factors Associated with Non-Adherence to Oral Medication for Inflammatory Bowel Disease: A Systematic Review. The American Journal of Gastroenterology, 105, 525-539.

[11]   Selinger, C.P., Eaden, J., Jones, D.B., et al. (2013) Modifiable Factors Associated with Nonadherence to Maintenance Medication for Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 19, 2199-2206.